Esperion Therapeutics, Inc.
182.3M
$646.60M
-33.91
$-0.11
No price alerts set. Add an alert to get notified!
-33.91
-2.55
$-0.11
7.51%
-5.63%
14.95%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ABSI
Absci Corporation
|
$4.92 | -1.11% | -6.43 | $764.80M | 0.03 |
|
AQST
Aquestive Therapeutics, Inc.
|
$4.20 | 2.44% | -6.11 | $417.09M | -3.90 |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
$15.46 | 1.78% | -79.88 | $1.30B | 0.02 |
|
EBS
Emergent BioSolutions Inc.
|
$8.47 | 2.92% | -51.12 | $437.43M | 1.10 |
|
OFIX
Orthofix Medical Inc.
|
$11.91 | 1.28% | -5.17 | $478.12M | 0.51 |
|
OLMA
Olema Pharmaceuticals, Inc.
|
$14.32 | -0.62% | -8.05 | $1.25B | 0.00 |
|
RGNX
REGENXBIO Inc.
|
$9.12 | 1.67% | -2.43 | $470.75M | 2.54 |
|
SIGA
SIGA Technologies, Inc.
|
$4.60 | 0.00 | 14.13 | $329.56M | 0.00 |
|
SNDL
SNDL Inc.
|
$1.41 | 3.68% | -45.45 | $365.47M | 0.15 |
|
VTYX
Ventyx Biosciences, Inc.
|
$14.00 | 0.00 | -9.36 | $1.00B | 0.05 |
* Peer stocks are selected based on market capitalization and sector
$4.18
$0.69
$0.00
0.00%
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
